Kiniksa Pharmaceuticals (Nasdaq:KNSA) today announced its plans to begin a Phase 2b trial using abiprubart in patients with Sjogren’s Disease.

This announcement comes alongside the release of data from Cohort 4 of the Phase 2 clinical trial of abiprubart for rheumatoid arthritis.

Abiprubart, a humanized anti-CD40 monoclonal antibody, aims to disrupt the CD40-CD154 interaction, a novel approach in the treatment of autoimmune diseases.

Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa, expressed optimism about abiprubart’s potential to make a significant impact on Sjogren’s disease, a condition currently lacking FDA-approved treatments.

Kiniksa’s strategy is backed by the strong revenue growth of ARCALYST and a solid cash position, enabling the company to pursue a strategic and disciplined capital allocation approach.

Patel added, “Based on our current operating plan, which includes progressing abiprubart through Phase 3 development for Sjogren’s Disease, we anticipate maintaining positive cash flow on an annual basis.”

This development signifies a critical step forward in Kiniksa’s commitment to addressing unmet medical needs in autoimmune diseases, potentially offering new hope to patients with Sjogren’s Disease.